Topic: graft-versus-host disease
The failure of the JAK1 inhibitor, which wiped $2 billion off Incyte’s market cap, is another blow to efforts to expand beyond Jakafi.
Mallinckrodt and Transimmune hope to expand the applications of extracorporeal photopheresis to several new indications.
The week’s biotech news included a potential boost to cancer immunotherapy and new insight into a dementia-causing protein.
Kalytera is developing cannabidiol for the prevention and treatment of graft-versus-host disease, a serious complication of bone marrow transplant.
The FDA lifted a clinical hold it placed on Bellicum's lead cell therapy, BPX-501, in January.
A late-stage study of Mesoblast’s off-the-shelf stem cell therapy for acute graft-versus-host disease (GVHD) has hit its main goal, setting up an imminent U.S. filing.
Ocugen has raised $7.5 million in a series B round as it fixes its sights on advancing a trio of eye disease treatments into clinical trials.
Adienne is planning an IPO in Switzerland to fund the advance if its graft-versus-host disease drug over the regulatory finish line.